ACLX-001 is a BCMA directed CAR T cell therapy in development for multiple myeloma.
SparkCures ID | 363 |
---|---|
Developed By | Arcellx, Inc. |
Generic Name | ACLX-001 |
Additional Names | CART-ddBCMA |
Treatment Classifications | |
Treatment Targets |
View all active clinical trials around the US.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
SparkCures Verified Accurate, up-to-date information. Learn more
June 03, 2022
Evaluable for efficacy and safety analysis were 31 patients, based on follow-up of at least one month, following treatment. These evaluable patients comprised the dose escalation cohorts for the first dose level (100 million CAR+ T cells, n=6), the second dose level (300 million CAR+T cells, n=6), and a dose expansion cohort at the recommended Phase 2 dose (RP2D) of 100 million CAR+T cells (n=19). All patients enrolled in the study have poor prognostic factors with 21 of 31 (68%) patients penta-refractory, 12 of 31 (39%) extramedullary disease (EMD), and all 31 patients having had at least three prior treatments.
The interim CART-ddBCMA clinical results (May 3, 2022 cutoff date) demonstrate deep and durable responses in patients with poor prognostic factors.